Physician profile
Sanaullah Sameer Khalid
NPI 1811285562
$266,505.92
in general payments reported to CMS, 2019-2025
76 companies · $53K in 2025
The $53K reported for 2025 was more than what 97% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $43K · 2020: $15K · 2021: $12K · 2022: $23K · 2023: $62K · 2024: $58K · 2025: $53K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $139K · Consulting Fee: $16K · Food and Beverage: $11K · Travel and Lodging: $6,831 · Education: $131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $138,940.00 |
| Consulting Fee | $15,950.00 |
| Food and Beverage | $11,366.38 |
| Travel and Lodging | $6,831.19 |
| Education | $131.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $170,847.75 | 2019-2025 | Opdivo, Opdualag |
| Jazz Pharmaceuticals INC. | $47,432.51 | 2021-2025 | Zepzelca |
| Merck Sharp & Dohme LLC | $9,508.93 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Verastem, INC. | $7,920.00 | 2019 | |
| Glaxosmithkline, LLC. | $7,621.15 | 2020-2025 | Ojjaara, Shingrix, Jemperli |
| Sun Pharmaceutical Industries INC. | $5,504.47 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $3,163.79 | 2019-2025 | Imfinzi, Lynparza, Enhertu |
| Sirtex Medical INC | $2,694.93 | 2024 | Sir-Spheres Microspheres |
| Celgene Corporation | $1,136.84 | 2019-2025 | Opdivo, Reblozyl, Opdualag |
| Novartis Pharmaceuticals Corporation | $996.03 | 2019-2025 | |
| Pfizer INC. | $898.95 | 2019-2025 | |
| Emd Serono, INC. | $757.89 | 2019-2025 | Tepmetko, Bavencio |
| Beigene USA, INC. | $578.06 | 2022-2024 | Brukinsa, Tevimbra |
| Takeda Pharmaceuticals U.S.A., INC. | $550.82 | 2019-2025 | Fruzaqla, Alunbrig, Iclusig |
| Genzyme Corporation | $467.74 | 2019-2025 |
Show all 76 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $426.38 | 2019-2025 | Tecvayli, Erleada, Darzalex |
| Abbvie INC. | $381.96 | 2024-2025 | |
| Astellas Pharma US INC | $346.11 | 2019-2025 | Xtandi, Vyloy, Padcev |
| Asd Specialty Healthcare, LLC | $290.27 | 2019-2021 | |
| Daiichi Sankyo INC. | $277.58 | 2019-2025 | Enhertu, Datroway, Vanflyta |
| Eisai INC. | $271.79 | 2019-2025 | |
| Amgen INC. | $256.65 | 2019-2022 | |
| Lilly USA, LLC | $253.42 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Genentech USA, INC. | $244.02 | 2019-2023 | Tecentriq, Perjeta, Venclexta |
| Exelixis INC. | $230.55 | 2019-2025 | Cabometyx |
| Pharmacyclics LLC, An Abbvie Company | $220.77 | 2019-2023 | Imbruvica, Epkinly |
| Acrotech Biopharma INC. | $201.30 | 2022-2025 | Beleodaq |
| Incyte Corporation | $198.52 | 2019-2025 | Monjuvi, Pemazyre, Jakafi |
| Bayer Healthcare Pharmaceuticals INC. | $165.60 | 2019-2025 | |
| Ipsen Biopharmaceuticals, INC | $165.06 | 2019-2025 | Onivyde, Tazverik, Somatuline Depot |
| Array Biopharma INC | $156.50 | 2022-2025 | Braftovi, Mektovi, Lorbrena |
| Aveo Pharmaceuticals, INC. | $146.27 | 2023-2025 | Fotivda |
| Regeneron Healthcare Solutions, INC. | $130.49 | 2023-2025 | Libtayo, Lynozyfic |
| Seagen INC. | $106.79 | 2022-2023 | Adcetris, Padcev |
| Genmab U.S., INC. | $103.98 | 2023-2025 | Tivdak, Epkinly |
| Stemline Therapeutics INC. | $100.95 | 2023-2025 | Orserdu |
| Rigel Pharmaceuticals, INC. | $94.59 | 2019-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Gilead Sciences, INC. | $92.57 | 2019-2025 | Trodelvy |
| Myovant Sciences INC. | $92.41 | 2021-2022 | |
| Adc Therapeutics America, INC. | $91.10 | 2023-2025 | |
| Kyowa Kirin, INC. | $88.56 | 2019-2024 | Poteligeo |
| Alexion Pharmaceuticals, INC. | $86.33 | 2019-2023 | Ultomiris |
| Beone Medicines USA, INC. | $78.33 | 2025 | Brukinsa, Tevimbra |
| Sumitomo Pharma America, INC. | $78.14 | 2023-2024 | Orgovyx |
| Blueprint Medicines Corporation | $77.25 | 2022-2024 | Ayvakit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.77 | 2019-2025 | |
| Karyopharm Therapeutics INC. | $71.49 | 2020-2025 | Xpovio |
| Heron Therapeutics, INC. | $60.61 | 2019-2022 | |
| Tesaro, INC. | $58.31 | 2019 | |
| Caris Mpi, INC. | $49.71 | 2025 | Mi Cancer Seek |
| Pharmacosmos Therapeutics INC. | $48.03 | 2023-2025 | Monoferric, Cosela |
| Dendreon Pharmaceuticals LLC | $40.50 | 2019-2025 | Provenge |
| Sobi, INC | $39.66 | 2022-2023 | |
| Emmaus Medical, INC. | $39.59 | 2020-2023 | Endari |
| Tolmar, INC. | $37.73 | 2023-2024 | |
| Puma Biotechnology, INC. | $37.00 | 2025 | |
| Morphosys, US INC. | $33.05 | 2023 | Monjuvi |
| Tolmar Pharmaceuticals, INC. | $32.87 | 2020-2022 | |
| Dova Pharmaceuticals | $30.27 | 2019-2020 | |
| Taiho Oncology, INC. | $28.57 | 2023 | |
| Fennec Pharmaceuticals, INC. | $24.47 | 2025 | Fyarro |
| Geron Corporation | $22.77 | 2025 | Rytelo |
| Springworks Therapeutics, INC. | $22.27 | 2025 | Ogsiveo |
| Myriad Genetic Laboratories, INC. | $22.07 | 2023 | Precisetumor |
| Apellis Pharmaceuticals, INC. | $19.06 | 2023 | Empaveli |
| Pharmaessentia USA Corporation | $18.88 | 2025 | Besremi |
| Tempus Ai, INC | $18.76 | 2024 | |
| Mirati Therapeutics, INC. | $18.72 | 2024 | Krazati |
| Secura Bio, INC. | $17.02 | 2020 | |
| Aurobindo Pharma USA, INC. | $16.60 | 2020 | |
| Aadi Bioscience, INC. | $16.57 | 2024 | Fyarro |
| G1 Therapeutics, INC. | $16.40 | 2023 | Cosela |
| Amneal Pharmaceuticals LLC | $16.22 | 2023 | Neupogen, Avastin, Neulasta |
| Tersera Therapeutics LLC | $15.08 | 2025 | Zoladex |
| Adaptive Biotechnologies Corporation | $14.86 | 2022 | |
| Shionogi INC | $10.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanaullah Khalid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.